Susanne Max Radke

RETWEET if you stand with the Obamas against Trump’s racist attacks!

OBAMA: “People make excuses for him. They say he’s not serious. Everything a president says is serious!”🔥

🔥hot off the press 👉ESMO-MCBS 2.0 Scorecards now available 🧐Do you agree with the proposed benefit? 👇Check them out for Hepatocellular Carcinoma esmo.org/guidelines/esm… @myESMO @ILCAnews @EASLedu

🔥hot off the press 👉ESMO-MCBS 2.0 Scorecards now available 🧐Do you agree with the proposed benefit? 👇Check them out for Cholangiocarcinoma esmo.org/guidelines/esm… @myESMO @ILCAnews @EASLedu

How to write a literature review 🖋️💡

Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma @JHepatology doi.org/10.1016/j.jhep… 👏Very comprehensive review on liquid and tissue biopsy in HCC 😅It's not a battle, it complements each other ... @myESMO @EASLnews @ILCAnews #livertwitter

Pleased to share PAGA guideline for #gastriccancer. Really appreciate Asian & European experts @LizzySmyth1 @tfleitask @GPentheroudakis @AndresC27622123 who joined the discussion. Thank you @myESMO and @JSMO_official for excellent support. esmoopen.com/article/S2059-…

Happy to share review of zolbetuximab for #gastriccancer. Regulatory approval still awaited. journals.sagepub.com/doi/full/10.11…

🔥Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing Cancer Treatment Reviews doi.org/10.1016/j.ctrv… 👉Understand all the advantages & disadvantages of hybrid capture vs amplicon-based enrichment and DNA vs RNA based NGS @myESMO @EASLedu @ILCAnews @curecc #livertwitter

@StephenVLiu @HosseinBorghaei @DrSteveMartin Happy Birthday! 🎁

A warm #NYLung23 Happy Birthday to our best friend @HosseinBorghaei from @DrSteveMartin and the whole team

@rachnatshroff @UAZHemeOnc @UAZCancer @UAZMedTucson @UAZHealth @UAZWIMSTucson Congratulations 🍾

The cat is finally out of the bag…so excited to lead @UAZHemeOnc and to partner with @UAZCancer to take the @UAZMedTucson Division of Heme/Onc to new heights! @UAZHealth @UAZWIMSTucson deptmedicine.arizona.edu/news/2023/dr-r…

📢📢 Less than a week to go until #ESMO23⏳ @myESMO asked the Upper GI track chair 👩‍⚕️ to share some upcoming highlights below ⬇️ Whether you're on a ✈️, 🚝 or watching 💻 Friday 2pm CET is when the transformative Upper GI starts...see you in Madrid....

@LizzySmyth1 @myESMO @FlorianLordick @DrAngelaLamarca @MagnusNsurgonc @YJanjigianMD @KoheiShitara @tfleitask @RadkaObermanno1 @ldawsonmd @LorenzaRimassa Thank you! Looking forward to seeing you in Madrid as well!

DESTINY LUNG 02: #WCLC23 updated data; impressive activity but remain concerned about ILD.

Flaura-2: escalation from osi to osi + CT makes sense in pts with ‘hard to treat’ EGFRmut NSCLC: exon 21, brain mets, and probably if symptoms/high tumor burden since PS1 pts derive more benefit than PS0. ~5X more Gr3 AEs & no signal in OS: not obvious in all comers. #WCLC2023

🎉FLAURA2 in EGFR-mut aNSCLC is➕ Escalating 🏔️ ttx in blinded way provides toxicity, not all need intensive ttx. CT-DNA status before EGFR TKI (data from FLAURA) is poor prog marker.These are the patients who may benefit of intense ttx.Only more to some pts,not for all #WCLC23

Repotrectinib seems a potent drug in TKI naïve ROS1➕ aNSCLC. Hwv, data ~ to Taletrectinib.Challenge is pre-treated patients and repotrectinib data looks similar to others but this drug acts against acquired G2032 ROS1 mut (not lorlatinib). Genomic profile at PD relevant #WCLC23

TRIDENT trial repotrectinib update. Impressive ORR, DOR and icPFS in ROS1 TKI naive. High activity post 1 TKI. Pleased to see responses in G2032R #WCLC23

Dr. Clarke: CODEBREAK101 soto960mg+carbo-pem: (SCARLET ORR 89%). Mainly cytopenias as expected. Higher AEs 2nd line(post IO). ORR 65% front line and 54% 2nd line. Await DOR and PFS #WCLC23

Loved this PROTAC strategy for “undrugable” targets. Really interesting early data that the concept works using G12D model #WCLC23